Anaplastic
astrocytoma is a grade III
tumor. It accounts for two percent of all brain tumors. It is a type of glioma
that develops from star-shaped glial cells (astrocytes), which support nerve
cells. Anaplastic astrocytoma grows faster and more aggressively than grade II
astrocytomas. The tumor cells are not uniform in appearance and invade
neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty
walking and seizures. Anaplastic astrocytoma is common among men and women in
their thirties to fifties and is more common in men than women. Treatment of
anaplastic astrocytoma depends on the location of the tumor and how far it has
progressed and usually involves surgery and radiation therapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline
guide Anaplastic Astrocytoma - Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Anaplastic Astrocytoma
(Oncology), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
Browse Detail Report With TOC @
The Anaplastic Astrocytoma (Oncology) pipeline
guide also reviews of key players involved in therapeutic development for
Anaplastic Astrocytoma and features dormant and discontinued projects. The
guide covers therapeutics under Development by Companies /Universities
/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase
I and Unknown stages are 4, 8, 11 and 1 respectively. Similarly, the
Universities portfolio in Phase II and Phase I stages comprises 1 and 2
molecules, respectively.
Anaplastic Astrocytoma (Oncology) pipeline
guide helps in identifying and tracking emerging players in the market and
their portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage. The guide is built
using data and information sourced from proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
Request A Sample copy of This
Report @ http://www.hexareports.com/report/anaplastic-astrocytoma-pipeline-review-h2-2017/request-sample
Note: Certain content / sections in the
pipeline guide may be removed or altered based on the availability and
relevance of data.
Scope
·
The pipeline
guide provides a snapshot of the global therapeutic landscape of Anaplastic
Astrocytoma (Oncology).
·
The pipeline
guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by
companies and universities/research institutes based on information derived
from company and industry-specific sources.
·
The pipeline
guide covers pipeline products based on several stages of development ranging
from pre-registration till discovery and undisclosed stages.
·
The pipeline
guide features descriptive drug profiles for the pipeline products which
comprise, product description, descriptive licensing and collaboration details,
R&D brief, MoA & other developmental activities.
·
The pipeline
guide reviews key companies involved in Anaplastic Astrocytoma (Oncology)
therapeutics and enlists all their major and minor projects.
·
The pipeline
guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on
mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type.
·
The pipeline
guide encapsulates all the dormant and discontinued pipeline projects.
Reasons To Buy
1. Procure strategically important competitor
information, analysis, and insights to formulate effective R&D strategies.
2. Recognize emerging players with potentially
strong product portfolio and create effective counter-strategies to gain
competitive advantage.
3. Find and recognize significant and varied
types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
4. Classify potential new clients or partners in
the target demographic.
5. Develop tactical initiatives by understanding
the focus areas of leading companies.
6. Plan mergers and acquisitions meritoriously by
identifying key players and it's most promising pipeline therapeutics.
7. Formulate corrective measures for pipeline
projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and
focus of Indication therapeutics.
8. Develop and design in-licensing and
out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and Scope.
9. Adjust the therapeutic portfolio by
recognizing discontinued projects and understand from the know-how what drove
them from pipeline.
Browse More Pharmaceuticals
& Healthcare Related Market Research Reports:
• Chronic
Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 -
• Non-Hodgkin Lymphoma - Pipeline Review, H1 2017
-
• Chondrosarcoma
- Pipeline Review, H1 2017 -
http://www.hexareports.com/report/chondrosarcoma-pipeline-review-h1-2017
No comments:
Post a Comment